Oxygenta Pharmaceutical Limited
BSE: OXYGENTAPH · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Oxygenta Pharmaceutical Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Oxygenta Pharma Limited is an Indian pharmaceutical company based in Hyderabad that specialises in the production of bulk drugs and active pharmaceutical ingredients (APIs). The company focuses on manufacturing chemical intermediates and generic drug components for both domestic and international markets.
Business Model
The company generates revenue through the manufacturing and marketing of pharmaceutical products, with a specific focus on contract manufacturing and cost-effective generic drug development.
Management Commentary
The company has recently undergone corporate restructuring and rebranding to better align its operations with long-term growth strategies in the life sciences sector.
Growth Outlook
Growth is expected to be driven by the company's strategic focus on expanding its footprint in the life sciences sector and leveraging its manufacturing capabilities for generic drug components.
Key Risks
- Regulatory Compliance. The pharmaceutical industry is subject to stringent quality and safety regulations that can impact manufacturing operations if standards are not met.
- Market Competition. The company faces intense competition from both domestic and international players in the generic drug and API manufacturing space.
- Supply Chain Volatility. Fluctuations in the cost and availability of raw chemical materials can significantly affect profit margins.
Start your research today
Unlock AI insights, financials, peers and live data on Oxygenta Pharmaceutical Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹113 Cr
TTM · standalone
NET PROFIT
₹18 Cr
TTM · standalone
EPS
₹4.75
TTM · standalone
RETURN ON EQUITY
58.8%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
441.6%
TTM · standalone
P/E
10.6x
Q4 FY26 · standalone
EV/EBITDA
9.6x
Q4 FY26 · standalone
EBITDA MARGIN
26.4%
TTM · standalone
NET PROFIT MARGIN
3.4%
Q4 FY26 · standalone
DEBT TO EQUITY
2.6x
Q4 FY26 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Oxygenta Pharmaceutical LimitedOXYGENTAPH | ₹214 Cr | 12.16 | 10.84 | 3.3% | 26.4% | 58.8% | 441.6% | -25.5% |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Q4 FY26
Financials
Oxygenta Pharmaceutical Limited
BSE: OXYGENTAPH · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Oxygenta Pharmaceutical Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Oxygenta Pharma Limited is an Indian pharmaceutical company based in Hyderabad that specialises in the production of bulk drugs and active pharmaceutical ingredients (APIs). The company focuses on manufacturing chemical intermediates and generic drug components for both domestic and international markets.
Business Model
The company generates revenue through the manufacturing and marketing of pharmaceutical products, with a specific focus on contract manufacturing and cost-effective generic drug development.
Management Commentary
The company has recently undergone corporate restructuring and rebranding to better align its operations with long-term growth strategies in the life sciences sector.
Growth Outlook
Growth is expected to be driven by the company's strategic focus on expanding its footprint in the life sciences sector and leveraging its manufacturing capabilities for generic drug components.
Key Risks
- Regulatory Compliance. The pharmaceutical industry is subject to stringent quality and safety regulations that can impact manufacturing operations if standards are not met.
- Market Competition. The company faces intense competition from both domestic and international players in the generic drug and API manufacturing space.
- Supply Chain Volatility. Fluctuations in the cost and availability of raw chemical materials can significantly affect profit margins.
Start your research today
Unlock AI insights, financials, peers and live data on Oxygenta Pharmaceutical Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹113 Cr
TTM · standalone
NET PROFIT
₹18 Cr
TTM · standalone
EPS
₹4.75
TTM · standalone
RETURN ON EQUITY
58.8%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
441.6%
TTM · standalone
P/E
10.6x
Q4 FY26 · standalone
EV/EBITDA
9.6x
Q4 FY26 · standalone
EBITDA MARGIN
26.4%
TTM · standalone
NET PROFIT MARGIN
3.4%
Q4 FY26 · standalone
DEBT TO EQUITY
2.6x
Q4 FY26 · standalone
Peers · Pharmaceuticals
As of Q4 FY26